Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Icosavax stock tanks after announcing disappointing interim SARS-CoV-2 Phase 1/2 results 

By Brian Buntz | March 25, 2022

IcosavaxIcosavax (Nasdaq:ICVX) saw its stock skid 65.5% to $4.26 in mid-day trading after announcing interim results from an ongoing Phase 1/2 trial of IVX-411, a virus-like particle vaccine candidate against SARS-CoV-2.

After going public last July, the company’s stock hit a peak of $39.73 on September 3.

Initial data from IVX-411 was comparable or below human convalescent sera control in previously unvaccinated individuals.

Three weeks after receiving the second vaccine dose, participants’ responses were up to 154 IU/mL across dosage groups in the live virus neutralization assay and up to 592 BAU/mL across groups in the spike IgG assay. The corresponding human convalescent sera control figures were 281 IU/mL and 361 BAU/mL, respectively.

In previously vaccinated participants, an IVX-411 booster drove up neutralizing antibody titers 5x to 599 IU/mL for wild-type virus after 28 days. For the omicron variant, neutralizing antibody titers were as much as eight-fold lower than for the wild-type virus.

Icosvax chief medical officer Niranjan Kanesa-thasan noted in a news release that the immunologic response was “below our expectations.”

“We plan to investigate the potential causes of these discordant clinical results, including manufacture, shipment, and administration of the product,” said Icosavax CEO Adam Simpson.

The study recruited 84 SARS-CoV-2 naive individuals and 84 previously vaccinated adults.

Before going public, Icosavax announced that it had closed $100 million in Series B financing, which it set aside for the development of its SARS-CoV-2 vaccine candidate.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Icosavax
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50